Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The brain RAS and Alzheimer's disease.

Wright JW, Harding JW.

Exp Neurol. 2010 Jun;223(2):326-33. doi: 10.1016/j.expneurol.2009.09.012. Epub 2009 Sep 24. Review.

PMID:
19782074
2.

Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.

Gard PR.

Expert Opin Ther Targets. 2004 Feb;8(1):7-14. Review.

PMID:
14996614
3.
4.

Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

Fournier A, Oprisiu-Fournier R, Serot JM, Godefroy O, Achard JM, Faure S, Mazouz H, Temmar M, Albu A, Bordet R, Hanon O, Gueyffier F, Wang J, Black S, Sato N.

Expert Rev Neurother. 2009 Sep;9(9):1413-31. doi: 10.1586/ern.09.89. Review.

PMID:
19769454
5.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
6.

The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease.

Wright JW, Harding JW.

J Renin Angiotensin Aldosterone Syst. 2008 Dec;9(4):226-37. doi: 10.1177/1470320308099084. Review.

PMID:
19126664
7.
8.

Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease.

Ashby EL, Kehoe PG.

Expert Opin Investig Drugs. 2013 Oct;22(10):1229-42. doi: 10.1517/13543784.2013.812631. Epub 2013 Jun 26. Review.

PMID:
23800077
9.

Angiotensin receptor blockers: evidence for preserving target organs.

Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM.

Clin Cardiol. 2001 Mar;24(3):183-90.

10.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
11.

[Therapy of Alzheimer disease].

Kovács T.

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Review. Hungarian.

12.

Inhibition of the renin-angiotensin system and the prevention of stroke.

Schrader J, Kulschewski A, Dendorfer A.

Am J Cardiovasc Drugs. 2007;7(1):25-37.

PMID:
17355164
13.

Angiotensin and Alzheimer's disease: therapeutic prospects.

Gard PR, Rusted JM.

Expert Rev Neurother. 2004 Jan;4(1):87-96. Review.

PMID:
15853619
14.

The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential.

Takeda S, Sato N, Ogihara T, Morishita R.

Front Biosci. 2008 Jan 1;13:2253-65. Review.

PMID:
17981707
15.
16.

Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.

Scott BB, McGeehan GM, Harrison RK.

Curr Protein Pept Sci. 2006 Jun;7(3):241-54. Review.

PMID:
16787263
17.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
18.

Angiotensin converting enzyme inhibitors and moderate hypertension.

McAreavey D, Robertson JI.

Drugs. 1990 Sep;40(3):326-45. Review.

PMID:
2226219
19.

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.

Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME.

J Hypertens. 2005 Mar;23(3):463-73. Review.

PMID:
15716683
20.

[Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].

Abassi Z, Armaly Z, Nakhoul F, Hoffman A.

Harefuah. 2008 Jun;147(6):536-42, 573. Review. Hebrew.

PMID:
18693632

Supplemental Content

Support Center